About OptiNose
OptiNose is a company based in Morrisville (United States) founded in 2000 was acquired by Paratek Pharma in March 2025. OptiNose has raised $120.5 million across 10 funding rounds from investors including Fidelity Investments, Paratek Pharma and bpcruk. The company has 132 employees. OptiNose offers products and services including XHANCE, ONZETRA, and Xsail. OptiNose operates in a competitive market with competitors including MannKind Corp, Impel NeuroPharma, Alexza, Qnovia and Iconovo, among others.
- Headquarter Morrisville, United States
- Employees 132
- Stage Public
- SectorsHealthcare
- Website optinose.com
- Social LinkedIn
- Acquired by Paratek Pharma (Mar 2025)
- Legal Name Optinose Us, Inc.
- Annual Revenue$76.28 M (USD)2as on Dec 31, 2022
- Total Equity Funding$120.5M (USD)
in 10 rounds
- Latest Funding Round$4.68M (USD), Post-IPO
May 2024
- InvestorsFidelity Investments
& 6 more
- Employee Count132
- Acquired byParatek Pharma
(Mar 2025)
Products & Services of OptiNose
OptiNose offers a comprehensive portfolio of products and services, including XHANCE, ONZETRA, and Xsail.
Delivers steroid for treating nasal inflammation in ENT conditions.
Exhalation delivery system for migraine relief medication.
Nasal device for effective medication administration in allergies.
Funding Insights of OptiNose
OptiNose has successfully raised a total of $120.5M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4.68 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $120.5M
- Total Rounds 10
- Last Round Post-IPO — $4.68M
- First Round $48.5M
(Jun 2010)
- Investors Count 6
All 10 funding rounds of OptiNose with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $4.68M | Post-IPO | – | – | – |
| Nov 2021 | $4M | Post-IPO | – | – | – |
| Aug 2020 | $250,000 | Post-IPO | – | – | – |
| Sep 2019 | $5.45M | Post-IPO | – | – | – |
| Sep 2019 | $150M | Debt – Conventional | – | – | |
| Dec 2017 | – | Post-IPO | – | – | |
| Apr 2017 | $37M | Series D | – | Fidelity Investments | |
| Oct 2015 | $35M | Series D | – | WFD Ventures, Entrepreneurs Fund | – |
| Aug 2014 | – | Series C | – | – | |
| Jun 2010 | $48.5M | Series B | – | – |
7 investors in total: 7 institutional.
Investors in OptiNose
OptiNose has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Paratek Pharma and bpcruk.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed by the firm. | – | athyrium.com | New York, United States | |
Tech & life science focused stage agnostic VC firm investing primarily in Western Europe | – | entrepreneursfund.com | London, United Kingdom | |
- | – | wfdventures.com | - | |
Provider of marketing services to biopharma sector | 2016 | bpcruk.com | United Kingdom | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Private equity investments are focused on the United States market. | – | avistacap.com | New York, United States | |
Therapeutics for antimicrobial resistant infections are developed. | 1996 | paratekpharma.com | Boston, United States |
Investor details for OptiNose
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OptiNose
25 people are tracked at OptiNose (13 in leadership, 5 in board & advisors, 7 in team); the tracked headcount is 132.
| Name | Role | Group |
|---|---|---|
Lee Lockard | Executive Director Market-access (clt Member) | Leadership |
Jilliane Frederick | Associate Director, Regulatory And Quality Operations | Leadership |
Ramy A. Mahmoud | CEO & Director | Leadership |
Mike Marino | Chief Legal Officer | Leadership |
Karen E. Brophy | Chief Human Resources Officer | Leadership |
Jonathan Neely | VP, Investor Relations, & Business Development | Leadership |
Deann L. Kenehan | Director, Thought Leader Engagement | Leadership |
Cindy Lehrer | Senior Director Of Human Resources | Leadership |
Stephen King | Sr. Director IT | Leadership |
Renee Marotta | Vice President Marketing | Leadership |
Bogdan Butoi | Vice President Of Information Technology | Leadership |
Ben Porter | Regional Business Director | Leadership |
Pamela Gray | Sr. Director, Quality | Leadership |
R. John Fletcher | Director | Board & advisors |
Kyle Dempsey | Director | Board & advisors |
Wilhelmus Groenhuysen | Director | Board & advisors |
Catherine E. Owen | Director | Board & advisors |
Tomas J. Heyman | Director | Board & advisors |
Joe Perrin | Manager, Financial A Information Systems | Team |
Ramona Lloyd | SVP, Regulatory & Quality | Team |
5 more people are available in the full profile.
Complete people profiles for OptiNose
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of OptiNose
5 dated milestones of OptiNose across 25 years, from founding to its latest funding, stage changes and deals.
- Founded OptiNose is founded.
- Funding First funding round of $48.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $4.7M.
- Exit Acquired by Paratek Pharma.
Competitors of OptiNose
OptiNose operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, Impel NeuroPharma, Alexza, Qnovia and Iconovo, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| impelnp.com | 2008 | Seattle, United States | $126.83M | 158 | Intranasal delivery technology for CNS diseases is developed. | |
| alexza.com | 2000 | Mountain View, United States | $97M | 72 | Developer of products for the treatment of acute and intermittent conditions | |
| qnovia.com | 2018 | Richmond, United States | $38.12M | – | Inhaled drug delivery devices are developed for pharmaceuticals. | |
| iconovo.se | 2013 | Lund, Sweden | $3.56M | – | Inhalation devices for medical applications are developed by Iconovo. | |
| aerami.com | 2010 | Durham, United States | $151.1M | – | Therapeutics for cardiopulmonary diseases are developed using inhaled therapies. | |
| nobhilltherapeutics.com | 2016 | Albuquerque, United States | $3.67M | – | Dry powder nebulizer is developed for targeted lung drug delivery. | |
| beyondair.net | 2011 | Garden, United States | – | – | Developer of device for treating respiratory conditions | |
| nebuflow.com | 2019 | Glasgow, United Kingdom | $7.97M | – | Aerosol delivery platform technology is developed for medical applications. |
Detailed competitors of OptiNose
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OptiNose
The website of OptiNose (optinose.com) receives about 5.1K visits a month.
- Monthly visits5.1K
▼ 10.4% vs previous month
Latest news on Optinose
Complete news archive for OptiNose
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to OptiNose
10 companies that operate in the same segment as OptiNose (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OptiNose
OptiNose was founded in 2000 and raised its 1st funding round 10 years after it was founded.
OptiNose is headquartered in Morrisville, United States.
OptiNose is a funded company, having raised a total of $120.5M across 10 funding rounds to date. The company's 1st funding round was a Series B of $48.5M, raised on Jun 2010.
OptiNose has 132 employees.
Annual revenue of OptiNose is $76.28M as on Dec 31, 2022.
OptiNose is a developer of smart devices for nasal drug delivery. The drug delivery devices can be used for powder and liquid formulations. Pipeline includes candidates for chronic nasal inflammatory disease, migraine and autism.
OptiNose's top competitors include MannKind Corp, Impel NeuroPharma and Qnovia.
OptiNose offers XHANCE, ONZETRA, and Xsail.
OptiNose has 7 investors. Key investors include Fidelity Investments, Paratek Pharma, bpcruk, Athyrium Capital Management, and Avista Capital Partners.
OptiNose operates through Optinose Us, Inc..
Yes. OptiNose was acquired by Paratek Pharma in March 2025.